https://prismbiolab.com/latest-news/ 2026-06-23T01:00:17+00:00 https://prismbiolab.com/ja/latest-news/ 2026-06-23T10:00:17+09:00 https://prismbiolab.com/latest-news/notice-of-our-merger/ 2018-11-12T07:00:28+00:00 https://prismbiolab.com/ja/latest-news/notice-of-our-merger/ 2018-11-12T16:00:28+09:00 https://prismbiolab.com/latest-news/prism-biolab-and-boehringer-ingelheim-enter-multi-project-drug-discovery-collaboration/ 2020-06-08T06:55:08+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-and-boehringer-ingelheim-enter-multi-project-drug-discovery-collaboration/ 2020-06-08T15:55:08+09:00 https://prismbiolab.com/latest-news/prism-biolab-and-merck-enter-multi-project-drug-discovery-collaboration/ 2020-11-04T06:48:22+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-and-merck-enter-multi-project-drug-discovery-collaboration/ 2020-11-04T15:48:22+09:00 https://prismbiolab.com/latest-news/servier-and-prism-biolab-enter-drug-discovery-collaboration-for-a-novel-target/ 2021-06-16T06:45:20+00:00 https://prismbiolab.com/ja/latest-news/servier-and-prism-biolab-enter-drug-discovery-collaboration-for-a-novel-target/ 2021-06-16T15:45:20+09:00 https://prismbiolab.com/latest-news/deprotection-of-the-indole-nind-formyl-for-group-on-tryptophan-employing-a-new-reagent-nn-dimethylethylendiamine-dmeda-in-an-aqueous-solution/ 2021-09-08T07:33:00+00:00 https://prismbiolab.com/ja/latest-news/deprotection-of-the-indole-nind-formyl-for-group-on-tryptophan-employing-a-new-reagent-nn-dimethylethylendiamine-dmeda-in-an-aqueous-solution/ 2021-09-08T16:33:00+09:00 https://prismbiolab.com/latest-news/identification-of-new-agonists-of-urotensin-ii-from-a-cyclic-peptide-library/ 2021-09-08T07:35:20+00:00 https://prismbiolab.com/ja/latest-news/identification-of-new-agonists-of-urotensin-ii-from-a-cyclic-peptide-library/ 2021-09-08T16:35:20+09:00 https://prismbiolab.com/latest-news/deprotection-of-nin-formyl-group-on-tryptophan-by-application-of-new-reagent-12-dimethylethylendiamine-in-aqueous-solution/ 2021-09-08T07:37:34+00:00 https://prismbiolab.com/ja/latest-news/deprotection-of-nin-formyl-group-on-tryptophan-by-application-of-new-reagent-12-dimethylethylendiamine-in-aqueous-solution/ 2021-09-08T16:37:34+09:00 https://prismbiolab.com/latest-news/protein-protein-interaction-%e3%82%92%e3%82%bf%e3%83%bc%e3%82%b2%e3%83%83%e3%83%88%e3%81%a8%e3%81%97%e3%81%9f%e5%89%b5%e8%96%ac/ 2021-09-08T07:39:21+00:00 https://prismbiolab.com/ja/latest-news/protein-protein-interaction-をターゲットとした創薬/ 2021-09-08T16:39:21+09:00 https://prismbiolab.com/latest-news/three-dimensional-structural-diversity-oriented-peptidomimetics-based-on-the-cyclopropylic-strain/ 2021-09-08T07:41:34+00:00 https://prismbiolab.com/ja/latest-news/three-dimensional-structural-diversity-oriented-peptidomimetics-based-on-the-cyclopropylic-strain/ 2021-09-08T16:41:34+09:00 https://prismbiolab.com/latest-news/follow-up-prospective-compound-design-using-the-sar-matrix-method-and-matrix-derived-conditional-probabilities-of-activity/ 2021-09-08T07:43:19+00:00 https://prismbiolab.com/ja/latest-news/follow-up-prospective-compound-design-using-the-sar-matrix-method-and-matrix-derived-conditional-probabilities-of-activity/ 2021-09-08T16:43:19+09:00 https://prismbiolab.com/latest-news/establishment-of-an-intermittent-cold-stress-model-using-tupaia-belangeri-and-evaluation-of-compound-c737-targeting-neuron-restrictive-silencer-factor/ 2021-09-08T07:44:50+00:00 https://prismbiolab.com/ja/latest-news/establishment-of-an-intermittent-cold-stress-model-using-tupaia-belangeri-and-evaluation-of-compound-c737-targeting-neuron-restrictive-silencer-factor/ 2021-09-08T16:44:50+09:00 https://prismbiolab.com/latest-news/a-mimetic-of-the-msin3-binding-helix-of-nrsf-rest-ameliorates-abnormal-pain-behavior-in-chronic-pain-models/ 2021-09-08T07:46:16+00:00 https://prismbiolab.com/ja/latest-news/a-mimetic-of-the-msin3-binding-helix-of-nrsf-rest-ameliorates-abnormal-pain-behavior-in-chronic-pain-models/ 2021-09-08T16:46:16+09:00 https://prismbiolab.com/latest-news/the-novel-inhibitor-pri-724-for-wnt-%ce%b2-catenin-cbp-signaling-ameliorates-bleomycin-induced-pulmonary-fibrosis-in-mice/ 2021-09-08T07:47:58+00:00 https://prismbiolab.com/ja/latest-news/the-novel-inhibitor-pri-724-for-wnt-β-catenin-cbp-signaling-ameliorates-bleomycin-induced-pulmonary-fibrosis-in-mice/ 2021-09-08T16:47:58+09:00 https://prismbiolab.com/latest-news/ms-11-a-mimetic-of-the-msin3-binding-helix-in-nrsf-ameliorates-social-interaction-deficits-in-a-prenatal-valproic-acid-induced-autism-mouse-model/ 2021-09-08T07:49:40+00:00 https://prismbiolab.com/ja/latest-news/ms-11-a-mimetic-of-the-msin3-binding-helix-in-nrsf-ameliorates-social-interaction-deficits-in-a-prenatal-valproic-acid-induced-autism-mouse-model/ 2021-09-08T16:49:40+09:00 https://prismbiolab.com/latest-news/%ce%b2-catenin-signaling-inhibitors-icg-001-and-c-82-improve-fibrosis-in-preclinical-models-of-endometriosis/ 2021-09-08T07:51:19+00:00 https://prismbiolab.com/ja/latest-news/β-catenin-signaling-inhibitors-icg-001-and-c-82-improve-fibrosis-in-preclinical-models-of-endometriosis/ 2021-09-08T16:51:19+09:00 https://prismbiolab.com/latest-news/anti-tumor-activity-of-the-small-molecule-inhibitor-pri-724-against-%ce%b2-catenin-activated-hepatocellular-carcinoma/ 2021-09-08T07:53:00+00:00 https://prismbiolab.com/ja/latest-news/anti-tumor-activity-of-the-small-molecule-inhibitor-pri-724-against-β-catenin-activated-hepatocellular-carcinoma/ 2021-09-08T16:53:00+09:00 https://prismbiolab.com/latest-news/e7386-a-selective-inhibitor-of-the-interaction-between-%ce%b2-catenin-and-cbp-exerts-antitumor-activity-in-tumor-models-with-activated-canonical-wnt-signaling/ 2021-09-08T07:56:49+00:00 https://prismbiolab.com/ja/latest-news/e7386-a-selective-inhibitor-of-the-interaction-between-β-catenin-and-cbp-exerts-antitumor-activity-in-tumor-models-with-activated-canonical-wnt-signaling/ 2021-09-08T16:56:49+09:00 https://prismbiolab.com/latest-news/generalized-ensemble-method-study-a-helix-mimetic-compound-inhibits-protein-protein-interaction-by-long-range-and-short-range-intermolecular-interactions/ 2021-09-08T07:58:31+00:00 https://prismbiolab.com/ja/latest-news/generalized-ensemble-method-study-a-helix-mimetic-compound-inhibits-protein-protein-interaction-by-long-range-and-short-range-intermolecular-interactions/ 2021-09-08T16:58:31+09:00 https://prismbiolab.com/latest-news/prism-biolab-raised-1-3-billion-yen-in-series-c-funding/ 2021-09-09T07:16:10+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-raised-1-3-billion-yen-in-series-c-funding/ 2021-09-09T16:16:10+09:00 https://prismbiolab.com/latest-news/visualized-and-quantitative-conformational-analysis-of-peptidomimetics/ 2021-10-27T05:51:07+00:00 https://prismbiolab.com/ja/latest-news/visualized-and-quantitative-conformational-analysis-of-peptidomimetics/ 2021-10-27T14:51:07+09:00 https://prismbiolab.com/latest-news/the-paper-of-peptidemimetics-is-published-in-acs-omega/ 2021-10-28T08:02:37+00:00 https://prismbiolab.com/ja/latest-news/the-paper-of-peptidemimetics-is-published-in-acs-omega/ 2021-10-28T17:02:37+09:00 https://prismbiolab.com/latest-news/prism-biolab-raised-100-million-yen-in-series-c-funding-from-eisai/ 2021-11-01T02:30:20+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-raised-100-million-yen-in-series-c-funding-from-eisai/ 2021-11-01T11:30:20+09:00 https://prismbiolab.com/latest-news/the-creb-binding-protein-cbp-%ce%b2-catenin-inhibitor-e7386-co-created-by-eisai-and-prism-biolab-achieved-the-clinical-poc-proof-of-concept/ 2021-11-01T02:30:37+00:00 https://prismbiolab.com/ja/latest-news/the-creb-binding-protein-cbp-β-catenin-inhibitor-e7386-co-created-by-eisai-and-prism-biolab-achieved-the-clinical-poc-proof-of-concept/ 2021-11-01T11:30:37+09:00 https://prismbiolab.com/latest-news/prism-biolab-enters-multi-project-drug-discovery-collaboration-with-roche-and-genentech/ 2022-01-04T13:00:42+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-enters-multi-project-drug-discovery-collaboration-with-roche-and-genentech/ 2022-01-04T22:00:42+09:00 https://prismbiolab.com/latest-news/prism-biolab-wins-biotech-company-of-the-year-award-of-informa-pharma-intelligence-award-2022/ 2022-09-01T05:35:30+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-wins-biotech-company-of-the-year-award-of-informa-pharma-intelligence-award-2022/ 2022-09-01T14:35:30+09:00 https://prismbiolab.com/latest-news/pharma-intelligence-award-japan-2022-commemorative-webinar-ppi-inhibition-by-small-molecules-a-new-drug-discovery-paradigm/ 2022-10-31T14:50:27+00:00 https://prismbiolab.com/ja/latest-news/pharma-intelligence-award-japan-2022-commemorative-webinar-ppi-inhibition-by-small-molecules-a-new-drug-discovery-paradigm/ 2022-10-31T23:50:27+09:00 https://prismbiolab.com/latest-news/rational-strategy-for-designing-peptidomimetic-small-molecules-based-on-cyclic-peptides-targeting-protein-protein-interaction-between-ctla-4-and-b7-1/ 2023-01-13T20:46:44+00:00 https://prismbiolab.com/ja/latest-news/rational-strategy-for-designing-peptidomimetic-small-molecules-based-on-cyclic-peptides-targeting-protein-protein-interaction-between-ctla-4-and-b7-1/ 2023-01-14T05:46:44+09:00 https://prismbiolab.com/latest-news/new-study-by-prism-biolab-demonstrates-rational-design-of-small-molecule-inhibitors-of-ctla-4-and-b7-1-protein-protein-interaction-utilizing-only-a-sequence-of-a-binding-peptide/ 2023-01-13T20:53:41+00:00 https://prismbiolab.com/ja/latest-news/new-study-by-prism-biolab-demonstrates-rational-design-of-small-molecule-inhibitors-of-ctla-4-and-b7-1-protein-protein-interaction-utilizing-only-a-sequence-of-a-binding-peptide/ 2023-01-14T05:53:41+09:00 https://prismbiolab.com/latest-news/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical/ 2023-05-31T06:00:41+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical/ 2023-05-31T15:00:41+09:00 https://prismbiolab.com/latest-news/development-of-low-molecular-weight-compounds-targeting-the-cancer-associated-klf5-transcription-factor/ 2023-10-26T07:27:00+00:00 https://prismbiolab.com/ja/latest-news/development-of-low-molecular-weight-compounds-targeting-the-cancer-associated-klf5-transcription-factor/ 2023-10-26T16:27:00+09:00 https://prismbiolab.com/latest-news/prism-biolab-and-lilly-enter-into-a-drug-discovery-collaboration-on-a-protein-protein-interaction-target/ 2023-11-29T01:00:45+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-and-lilly-enter-into-a-drug-discovery-collaboration-on-a-protein-protein-interaction-target/ 2023-11-29T10:00:45+09:00 https://prismbiolab.com/latest-news/prism-biolab-raises-1-5-billion-yen-in-series-c-fundraising-to-advance-technologies-and-programs-targeting-protein-protein-interactions/ 2024-01-24T08:00:38+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-raises-1-5-billion-yen-in-series-c-fundraising-to-advance-technologies-and-programs-targeting-protein-protein-interactions/ 2024-01-24T17:00:38+09:00 https://prismbiolab.com/latest-news/announcement202404/ 2024-04-21T06:58:14+00:00 https://prismbiolab.com/ja/latest-news/announcement202404/ 2024-04-21T15:58:14+09:00 https://prismbiolab.com/latest-news/prism-biolab-enters-into-a-joint-research-and-licensing-agreement-with-ono/ 2024-04-25T06:00:07+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-enters-into-a-joint-research-and-licensing-agreement-with-ono/ 2024-04-25T15:00:07+09:00 https://prismbiolab.com/latest-news/notice-of-approval-for-listing-on-the-growth-market-of-the-tokyo-stock-exchange/ 2024-05-27T06:36:12+00:00 https://prismbiolab.com/ja/latest-news/notice-of-approval-for-listing-on-the-growth-market-of-the-tokyo-stock-exchange/ 2024-05-27T15:36:12+09:00 https://prismbiolab.com/latest-news/announcement-of-initial-listing-on-tokyo-stock-exchange-growth-market/ 2024-07-02T00:02:08+00:00 https://prismbiolab.com/ja/latest-news/announcement-of-initial-listing-on-tokyo-stock-exchange-growth-market/ 2024-07-02T09:02:08+09:00 https://prismbiolab.com/latest-news/prism-biolab-opens-a-business-office-in-tokyo/ 2024-09-02T00:14:56+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-opens-a-business-office-in-tokyo/ 2024-09-02T09:14:56+09:00 https://prismbiolab.com/latest-news/press_release_20240909/ 2024-09-09T00:00:13+00:00 https://prismbiolab.com/ja/latest-news/press_release_20240909/ 2024-09-09T09:00:13+09:00 https://prismbiolab.com/latest-news/notice-of-article-published-in-the-nikkei/ 2024-09-30T05:04:11+00:00 https://prismbiolab.com/ja/latest-news/notice-of-article-published-in-the-nikkei/ 2024-09-30T14:04:11+09:00 https://prismbiolab.com/latest-news/news_202410_01/ 2024-10-07T07:03:18+00:00 https://prismbiolab.com/ja/latest-news/news_202410_01/ 2024-10-07T16:03:18+09:00 https://prismbiolab.com/latest-news/202410_02/ 2024-10-23T07:36:30+00:00 https://prismbiolab.com/ja/latest-news/202410_02/ 2024-10-23T16:36:30+09:00 https://prismbiolab.com/latest-news/event-report-cto-toma-speaks-at-link-j-and-merck-co-hosted-symposium/ 2024-12-16T07:23:47+00:00 https://prismbiolab.com/ja/latest-news/event-report-cto-toma-speaks-at-link-j-and-merck-co-hosted-symposium/ 2024-12-16T16:23:47+09:00 https://prismbiolab.com/latest-news/our-ceo-takahara-featured-on-irtv-video-media/ 2024-12-16T07:23:56+00:00 https://prismbiolab.com/ja/latest-news/our-ceo-takahara-featured-on-irtv-video-media/ 2024-12-16T16:23:56+09:00 https://prismbiolab.com/latest-news/202412_01/ 2024-12-26T04:40:51+00:00 https://prismbiolab.com/ja/latest-news/202412_01/ 2024-12-26T13:40:51+09:00 https://prismbiolab.com/latest-news/announcement-participation-in-link-js-miyamans-venture-talk-vol-12/ 2025-02-20T16:52:55+00:00 https://prismbiolab.com/ja/latest-news/announcement-participation-in-link-js-miyamans-venture-talk-vol-12/ 2025-02-21T01:52:55+09:00 https://prismbiolab.com/latest-news/announcement-guest-appearance-on-radio-nikkei-1s-the-money-thursday-hideaki-sakurais-kabutetsu/ 2025-03-13T14:46:58+00:00 https://prismbiolab.com/ja/latest-news/announcement-guest-appearance-on-radio-nikkei-1s-the-money-thursday-hideaki-sakurais-kabutetsu/ 2025-03-13T23:46:58+09:00 https://prismbiolab.com/latest-news/prism-biolab-and-elix-join-forces-to-accelerate-ai-driven-drug-discovery-for-protein-protein-interaction-targets/ 2025-04-12T23:45:56+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-and-elix-join-forces-to-accelerate-ai-driven-drug-discovery-for-protein-protein-interaction-targets/ 2025-04-13T08:45:56+09:00 https://prismbiolab.com/latest-news/featured-in-the-nikkei/ 2025-04-14T00:15:30+00:00 https://prismbiolab.com/ja/latest-news/featured-in-the-nikkei/ 2025-04-14T09:15:30+09:00 https://prismbiolab.com/latest-news/featured-in-nikkei-biotech/ 2025-05-09T15:17:29+00:00 https://prismbiolab.com/ja/latest-news/featured-in-nikkei-biotech/ 2025-05-10T00:17:29+09:00 https://prismbiolab.com/latest-news/pepmetics-technology-enabling-the-control-of-protein-protein-interactions/ 2025-05-09T15:29:08+00:00 https://prismbiolab.com/ja/latest-news/pepmetics-technology-enabling-the-control-of-protein-protein-interactions/ 2025-05-10T00:29:08+09:00 https://prismbiolab.com/latest-news/announcement-investor-relations-seminar-for-individual-investors/ 2025-05-13T16:49:28+00:00 https://prismbiolab.com/ja/latest-news/announcement-investor-relations-seminar-for-individual-investors/ 2025-05-14T01:49:28+09:00 https://prismbiolab.com/latest-news/eisai-to-present-e7386-co-created-by-prism-biolab-and-eisai-at-the-asco-american-society-of-clinical-oncology-annual-meeting/ 2025-05-23T00:00:39+00:00 https://prismbiolab.com/ja/latest-news/eisai-to-present-e7386-co-created-by-prism-biolab-and-eisai-at-the-asco-american-society-of-clinical-oncology-annual-meeting/ 2025-05-23T09:00:39+09:00 https://prismbiolab.com/latest-news/prism-biolab-announces-patent-acquisition-for-pepmetics-technology-library-compounds/ 2025-06-09T03:00:37+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-announces-patent-acquisition-for-pepmetics-technology-library-compounds/ 2025-06-09T12:00:37+09:00 https://prismbiolab.com/latest-news/notice-of-termination-of-collaboration-and-licensing-agreement-with-eli-lilly-and-company/ 2025-08-01T20:12:26+00:00 https://prismbiolab.com/ja/latest-news/notice-of-termination-of-collaboration-and-licensing-agreement-with-eli-lilly-and-company/ 2025-08-02T05:12:26+09:00 https://prismbiolab.com/latest-news/notice-of-termination-of-collaboration-and-licensing-agreement-with-servier/ 2025-10-03T07:00:35+00:00 https://prismbiolab.com/ja/latest-news/notice-of-termination-of-collaboration-and-licensing-agreement-with-servier/ 2025-10-03T16:00:35+09:00 https://prismbiolab.com/latest-news/prism-biolab-announces-patent-grant-for-novel-bicyclic-pepmetics-compounds/ 2025-10-03T07:15:48+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-announces-patent-grant-for-novel-bicyclic-pepmetics-compounds/ 2025-10-03T16:15:48+09:00 https://prismbiolab.com/latest-news/eisai-to-present-clinical-trial-and-biomarker-exploration-results-of-e7386-co-created-with-prism-biolab-at-the-esmo-annual-congress/ 2025-10-20T16:49:00+00:00 https://prismbiolab.com/ja/latest-news/eisai-to-present-clinical-trial-and-biomarker-exploration-results-of-e7386-co-created-with-prism-biolab-at-the-esmo-annual-congress/ 2025-10-21T01:49:00+09:00 https://prismbiolab.com/latest-news/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical/ 2025-11-05T19:11:52+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-announces-initiation-of-patient-enrollment-in-a-phase-i-drug-drug-interaction-study-of-pri-724-by-ohara-pharmaceutical/ 2025-11-06T04:11:52+09:00 https://prismbiolab.com/latest-news/prism-biolab-announces-achievement-of-initial-milestone-and-receipt-of-upfront-payment-in-drug-discovery-collaboration-with-ono-pharmaceutical-co-ltd/ 2025-11-14T07:30:57+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-announces-achievement-of-initial-milestone-and-receipt-of-upfront-payment-in-drug-discovery-collaboration-with-ono-pharmaceutical-co-ltd/ 2025-11-14T16:30:57+09:00 https://prismbiolab.com/latest-news/financial-results-for-the-fiscal-year-ended-september-2025-japanese-gaap-non-consolidated/ 2025-11-17T18:34:24+00:00 https://prismbiolab.com/ja/latest-news/financial-results-for-the-fiscal-year-ended-september-2025-japanese-gaap-non-consolidated/ 2025-11-18T03:34:24+09:00 https://prismbiolab.com/latest-news/prism-biolab-announces-patent-grant-for-novel-bicyclic-pepmetics-compounds-2/ 2025-11-27T17:56:11+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-announces-patent-grant-for-novel-bicyclic-pepmetics-compounds-2/ 2025-11-28T02:56:11+09:00 https://prismbiolab.com/latest-news/prism-biolab-and-talus-bioscience-announce-joint-research-agreement/ 2025-12-17T17:00:31+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-and-talus-bioscience-announce-joint-research-agreement/ 2025-12-18T02:00:31+09:00 https://prismbiolab.com/latest-news/notice-of-tokyo-office-relocation/ 2026-01-19T21:06:47+00:00 https://prismbiolab.com/ja/latest-news/notice-of-tokyo-office-relocation/ 2026-01-20T06:06:47+09:00 https://prismbiolab.com/latest-news/phase-1-clinical-research-results-of-e7386-jointly-created-by-prismbiolab-and-eisai-published-in-esmo-open/ 2026-01-21T17:02:05+00:00 https://prismbiolab.com/ja/latest-news/phase-1-clinical-research-results-of-e7386-jointly-created-by-prismbiolab-and-eisai-published-in-esmo-open/ 2026-01-22T02:02:05+09:00 https://prismbiolab.com/latest-news/prism-biolab-and-receptor-ai-announce-drug-discovery-collaboration-agreement/ 2026-03-13T00:00:19+00:00 https://prismbiolab.com/ja/latest-news/prism-biolab-and-receptor-ai-announce-drug-discovery-collaboration-agreement/ 2026-03-13T09:00:19+09:00 https://prismbiolab.com/latest-news/eisai-to-present-preclinical-research-results-of-e7386-co-created-with-prism-biolab-at-the-aacr-annual-meeting-2026/ 2026-04-07T00:00:45+00:00 https://prismbiolab.com/ja/latest-news/eisai-to-present-preclinical-research-results-of-e7386-co-created-with-prism-biolab-at-the-aacr-annual-meeting-2026/ 2026-04-07T09:00:45+09:00 https://prismbiolab.com/latest-news/notice-of-allowance-for-pepmetics-technology-library-compounds-patent-in-the-united-states/ 2026-05-11T00:00:36+00:00 https://prismbiolab.com/ja/latest-news/notice-of-allowance-for-pepmetics-technology-library-compounds-patent-in-the-united-states/ 2026-05-11T09:00:36+09:00 https://prismbiolab.com/latest-news/notice-of-expiration-of-the-research-and-license-agreement-with-boehringer-ingelheim-international-gmbh/ 2026-05-18T00:00:24+00:00 https://prismbiolab.com/ja/latest-news/notice-of-expiration-of-the-research-and-license-agreement-with-boehringer-ingelheim-international-gmbh/ 2026-05-18T09:00:24+09:00 https://prismbiolab.com/latest-news/notice-of-participation-in-radio-nikkei-japan-tour/ 2026-05-21T23:30:23+00:00 https://prismbiolab.com/ja/latest-news/notice-of-participation-in-radio-nikkei-japan-tour/ 2026-05-22T08:30:23+09:00 https://prismbiolab.com/latest-news/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting/ 2026-05-25T07:00:40+00:00 https://prismbiolab.com/ja/latest-news/cardiac-safety-evaluation-results-from-phase-1-clinical-studies-of-e7386-jointly-created-by-prism-biolab-and-eisai-to-be-shared-by-eisai-at-the-asco-annual-meeting/ 2026-05-25T16:00:40+09:00 https://prismbiolab.com/latest-news/link-j-symposium-drug-discovery-frontier-2026-speaking-announcement/ 2026-06-08T07:00:59+00:00 https://prismbiolab.com/ja/latest-news/link-j-symposium-drug-discovery-frontier-2026-speaking-announcement/ 2026-06-08T16:00:59+09:00 https://prismbiolab.com/latest-news/notice-of-speaking-engagement-at-the-59th-natural-products-chemistry-discussion-meeting/ 2026-06-23T01:00:17+00:00 https://prismbiolab.com/ja/latest-news/notice-of-speaking-engagement-at-the-59th-natural-products-chemistry-discussion-meeting/ 2026-06-23T10:00:17+09:00